Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2008-04-30
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients
NCT00399204
Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus
NCT01082120
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
NCT03499704
Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus
NCT00232362
Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus
NCT00308373
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Arm A- Metformin
Metformin
500 mg of Metformin taken orally twice a day
B
Arm B- Pioglitazone
Pioglitazone
15mg of Pioglitazone taken orally twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pioglitazone
15mg of Pioglitazone taken orally twice a day
Metformin
500 mg of Metformin taken orally twice a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Permanent resident of Darwin for at least 1 year immediately before and expected to be for at least 1 year after study commences
* Participants must be able to give informed voluntary consent
* Both males and females (females of child bearing potential excluded if not on reliable means of contraception)
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Menzies School of Health Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Menzies School of Health Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Louise Maple Brown, MBBS PhD FRACP
Role: PRINCIPAL_INVESTIGATOR
Menzies School of Health Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Menzies School of Health Research
Darwin, Northern Territory, Australia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DART-MSHR-06-29
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.